Currently, a trend towards deintensification of sugar-lowering therapy has emerged in the domestic and international clinical practice of type 2 diabetes mellitus management. And while recently reducing the intensity of antidiabetic therapy was considered primarily for elderly patients in terms of reducing the risk of hypoglycemia, it is now recognized that many other patients could benefit especially by conversion from intensive insulin therapy regimens to simpler regimens (e. g., fixed combinations of GLP-1 RA and BI). Regimen simplification and reduced number of injections have been shown to improve adherence to therapy without compromising the quality of glycemic control.